P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Arvinas, Inc. (“Arvinas” or the ...

Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Fintel reports that on May 5, 2025, Truist Securities downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Buy to Hold.

Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised ...

The state of Connecticut “WARN” site that reports such layoffs indicates that 92 of the people to be laid off are state ...

Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $31.24, a 391.2% upside from current levels. In a report released yesterday, TD Cowen also maintained ...

Discover why biotech stock ARVN, trading at a 70% discount to cash value, offers potential upside despite setbacks.

There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its first-quarter report, with the stock down 15% to US$7.72. Revenues of 351% beat expectations by ...

New Haven-based Arvinas will lay off 131 employees, with 92 in Connecticut, as part of a major workforce reduction.

Since its inception in February 2018, the fund has returned annualized […] Arvinas Inc (ARVN) reports a significant revenue increase and outlines strategic moves to extend its cash runway and enhance ...

On Friday, Arvinas Inc. (NASDAQ:ARVN) stock rating was downgraded by TD Cowen from Buy to Hold following the announcement that partner Pfizer (NYSE:PFE) has canceled the 1L and 2L vepdeg/CDK4(6) ...